Newsletter
NEWS AND EVENTS
Home
Company
Pipeline
Investor Relations
News and Events
Contact
Privacy Policy
Disclaimer
Imprint
Archive Press
© relief therapeutics 2024
Latest News
Stay up to date on Relief activities
Corporate News
Archive
Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations
13 December 2024 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
11 November 2024 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger
4 November 2024 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE
29 October 2024 | non-Ad Hoc
Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents
25 October 2024 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment
21 October 2024 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
8 October 2024 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria
4 October 2024 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces $2 Million Milestone Under Royalty Sales Agreement
23 September 2024 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024
18 September 2024 | non-Ad Hoc
Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024
2 September 2024 | non-Ad Hoc
Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update
30 August 2024 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Secures up to $11 Million from Royalty Sales
5 August 2024 | Ad Hoc Announcement pursuant to Art. 53 LR
RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General Meeting
26 April 2024 | non-Ad Hoc
Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
1 September 2023 | non-Ad Hoc
Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE® in the U.S. with Pentec Health
19 July 2023 | non-Ad Hoc
Relief Therapeutics Announces Swissmedic Approval and Operation of New Good Manufacturing Practice-Compliant Laboratory
15 May 2023 | non-Ad Hoc
Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares
3 May 2023 | non-Ad Hoc
Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders
28 April 2023 | non-Ad Hoc
Relief Therapeutics Announces Availability of New PKU GOLIKE BARs in Europe
16 March 2023 | non-Ad Hoc
Company
Pipeline
Investor Relations
News and Events
© Relief Therapeutics